Landmark Study Demonstrates Safety and Effectiveness of Minimally Invasive Laser Interstitial Thermal Therapy (LITT) for Drug-Resistant Epilepsy

Strategic Insights -

A recent study published in JAMA Neurology has established LITT using the NeuroBlate System as a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical's 1,000+ patient LAANTERN research initiative, analyzed data from 145 patients across 15 U.S. institutions, providing the largest prospective analysis to date of LITT for drug-resistant epilepsy. The findings demonstrate long-term seizure freedom outcomes comparable to anterior temporal lobectomy (ATL), with 58.4% and 57.2% of patients achieving Engel 1 and International League Against Epilepsy (ILAE) 1/2 seizure freedom classifications at one and two years, respectively.

Key Takeaways:

  • The study represents the largest prospective analysis to date of LITT for drug-resistant epilepsy, with 145 patients across 15 U.S. institutions.
  • LITT using the NeuroBlate System has been shown to be safe, durable, and minimally invasive, with 58.4% and 57.2% of patients achieving Engel 1 and ILAE 1/2 seizure freedom classifications at one and two years, respectively.
  • Patients who underwent LITT experienced short hospitalizations, low readmission rates, and positive recovery outcomes, with nearly all discharged to their homes post-procedure.
  • The study highlights the superiority of LITT in terms of recovery benefits and lower complications compared to traditional surgery.
  • The NeuroBlate procedure involves making a small opening about the diameter of a pencil in the skull, allowing patients to often go home the next day with little or no pain.
  • The study showed that quality of life (QoL) improvements were observed at nearly every measured time point, highlighting the impact of minimally invasive NeuroBlate on patient well-being.
  • More than one-third (34.9%) of patients either stopped or reduced their use of anti-seizure medications following the procedure, emphasizing its long-term benefits.
  • Pediatric and adult patients were shown to experience comparable outcomes, confirming previously published evidence that LITT is a viable option for pediatric epilepsy.

Statistics:

  • 58.4% and 57.2% of patients achieved Engel 1 and ILAE 1/2 seizure freedom classifications at one and two years, respectively.
  • 34.9% of patients either stopped or reduced their use of anti-seizure medications following the procedure.
  • Pediatric and adult patients showed comparable outcomes, with 58.4% and 57.2% of pediatric patients achieving Engel 1 and ILAE 1/2 seizure freedom classifications at one and two years, respectively.
  • Patients who underwent LITT experienced short hospitalizations, with a mean hospital stay of 1.4 days.
  • The study showed a significant reduction in surgical time when using ROSA robotics for cranial access, with a mean time savings of 23 minutes compared to the Clearpoint Navigation System.

Sources:

  • "Landmark Study Demonstrates Safety and Effectiveness of Minimally Invasive Laser Interstitial Thermal Therapy (LITT) for Drug-Resistant Epilepsy." NewsRx, 2025 AUG 2
  • JAMA Neurology, 2025 AUG 2
  • Monteris Medical, "LAANTERN Study: LITT for Drug-Resistant Mesial Temporal Lobe Epilepsy."